StratDeck

Two stocks in Healthcare

argenx vs Gerresheimer: profit, growth, debt and price compared

argenx is stronger on 4 of 6 figures: profit margin, sales growth, debt and analysts' view. Gerresheimer is stronger on 2: price for its expected profit and price trend.

Figures as of 18 November 2026Yahoo Finance
Explore argenx's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

argenx and Gerresheimer side by side
argenxARGX.BRGerresheimerGXI.DE
Net marginStronger: 31.7%−17.5%
Revenue growth, past yearStronger: +52.10%−0.80%
Debt to equityStronger: 0.6%236.7%
Forward P/E26.9×Stronger: 13.5×
Dividend yield——
AnalystsStronger: Buy · 23Hold · 12
From its 200-day average+11.9%Stronger: +13.7%

Share price over the past year

  • argenx+9.4%
  • Gerresheimer+36.7%

24 Nov 202518 Nov 2026

argenx or Gerresheimer: which is stronger?

  • ARGX.BR

    Which is more profitable?

    argenx keeps more of each sale as profit: 31.7% against −17.5%.

  • ARGX.BR

    Which is growing its sales faster?

    argenx is growing its sales faster: +52.10% over the past year, against −0.80%.

  • ARGX.BR

    Which has borrowed less?

    argenx has borrowed less: its debt is 0.6% of what its shareholders own, against 236.7% for Gerresheimer.

  • GXI.DE

    Which costs less for the profit it is expected to make?

    Gerresheimer costs less for the profit it is expected to make: 13.5× its forward earnings, against 26.9×.

  • Which pays more in dividends?

    Neither pays a dividend.

  • ARGX.BR

    Which do analysts rate higher?

    Analysts are warmer on argenx: Buy, against Hold for Gerresheimer.

  • GXI.DE

    Which is in the stronger price trend?

    Gerresheimer's price is in the stronger trend: 13.7% above its 200-day average, against 11.9% above.

What each company does

ARGX.BRargenx

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.

Reports results on 25 February 2027

GXI.DEGerresheimer

Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally.

Reports results on 25 November 2026

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.